Takeda takes a cautious step into neurological gene therapy, inking preclinical deal with StrideBio

Saddled with debt and keen to divest non-core business amid the ongoing integration of Shire, Takeda has nevertheless dished out a small sum to beef up its neuroscience research capacities, enlisting Durham, NC-based StrideBio to get started on some preclinical gene therapy candidates.